

Express Mail No.: EL 501 759 175 US

IN THE UNITED STATES PATENT AND TRADEMARK

APR 1 1 2003

Application of: Langermann et al.

Confirmation No.: 9514

TECH CENTER 1600/2900

Application No.: 10/015,085

Group Art Unit: 1645

Filed: December 10, 2001

Examiner: To Be Assigned

Attorney Docket No.: 10271-037-999

For: MUTANT PROTEINS, HIGH POTENCY INHIBITORY ANTIBODIES AND FIMCH

CRYSTAL STRUCTURE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. \$1.56 AND \$1.97

Assistant Commissioner for Patents Washington, D.C. 20231 Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent Office of all references coming to the attention of Applicants or Attorneys for Applicants which are or may be material to the patentability of any claim of the aboveidentified application. Attorneys for Applicants hereby direct the Examiner's attention to the references BT-BW listed on the attached revised Form PTO 1449. A copy of each of the identified references is enclosed herewith.

Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Consequently, Applicants respectfully decline to use Form PTO-1449, since this form identifies all of the references cited therein as "Prior Art." As an alternative, Applicants submit herewith a "revised Form PTO 1449" entitled "List of References Cited by Applicant" instead of "List of Prior Art Cited."

Applicants request that the Examiner review all of the references identified on the attached revised Form PTO 1449 and make them of record in the file history of the above-identified application.

Pursuant to 37 C.F.R. § 1.97(b)(3), since this Supplemental Information
Disclosure Statement is believed to be filed before the mailing date of a first Office Action on
the merits, no fee is due in connection herewith. However, should the Patent Office
determine otherwise, please charge the required fee to Pennie & Edmonds LLP deposit
account no. 16-1150; a duplicate of this sheet is enclosed.

Respectfully submitted,

Date: __April 9, 2003

Anthony M. Insogna 35,203
Anthony M. Insogna (Reg. No.)

y: Margaret B. Brivanlou

(Reg. No.)

PENNIE & EDMONDS LLP 1155 Avenue of the Americas New York, New York 10036-2711 (212) 790-9090

							Expres	s Maii No <u>EL</u>	Sheet 1		
						ATTY DOCKET NO.:			APPLICATION NO.:		
						10271-037-999		10/015,085			
							APPLICANT:				
(Use cveral sheets if necessary)						Langermann et	CONFIRMATION NO.:				
(2)											
(NA 0 0 5000 25)						PILING DATE: December 10, 2	001	GROUP: 1645			
	NOVE S	- autit	U.S. PA	TENT I	OCUM		001	1045			
		TRADE		,							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME		CLASS	SUBCLASS	FILING I	DATE PRIATE	
							REC	CEIV	<u> </u>		
	_						1				
							AP	APR 1 1 2003			
	1				TECH OF				ENTER 1600/2900		
FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATE										ATION	
							1 02,00	LOGGERIO	YES	NO	
									T		
		OTHER REFERE	,		-						
	BT	Uringry Tract Infections" Laf Infectious Diseases 183(Suppl. 1): \$84.6									
	BU Schembri et al., 2001, "Molecular Characterization of the Escherichia coli FimH Adhesin", J. of Infectious Diseas.									ises V	
	BV										
	Urinary Tract Infections", J. of Infectious Diseases 183(Suppl. 1):S36-40. BW Uehling et al., 2001, "Vaginal Mucosal Immunization for Recurrent Urinary Tract Infection: Extended Phase II Clinical Trial", J. of Infectious Diseases 183(Suppl. 1):S81-3.										
		Common Trial , v. Of Injec	Diseases	, ros(sup)	1,	<u>. </u>				==	
EXAMINER					DATE C	CONSIDERED					
*EXAMINER:	Initial if	reference considered, whether	or not citation is i	in conformar	ice with MI	PEP 609; Draw line thro	ough citation	if not in confo	rmance and	not	
considered. Include copy of this form with next communication to applicant.											